Approval · Notice of Compliance 30501 · 2023
ABEVMY: Notice of Compliance 30501
Issued April 5, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30501
- Date
- April 5, 2023
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Drug product manufacturing process change
- Canadian reference product
- AVASTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABEVMY | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 100 MG per 4ML
- BEVACIZUMAB 400 MG per 4ML